Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 10/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396310 | 1.00 | THRB (0.59) | THRBTDP1APEX1PDK2KMT2A | |
| Bromide SCHEMBL27743798 | 0.98 | THRB (0.57) | THRBTDP1APEX1PDK2KMT2A | |
| Bromomethane SCHEMBL208930 | 0.94 | THRB (0.53) | THRBTDP1APEX1PDK2KMT2A | |
| Propanol SCHEMBL27803571 | 0.86 | THRB (0.46) | THRBTDP1APEX1PDK2 | |
| SCHEMBL28760722 | 0.77 | THRB (0.38) | THRBTDP1APEX1PDK2KMT2A | |
| SCHEMBL27621788 | 0.77 | ALOX5 (0.41) | THRBTDP1AKR1C1 | |
| SCHEMBL18663304 | 0.76 | THRB (0.64) | THRBTDP1APEX1PDK2KMT2A | |
| SCHEMBL15691557 | 0.76 | THRB (0.64) | THRBTDP1APEX1PDK2KMT2A | |
| SCHEMBL29608923 | 0.75 | PDK2 (0.50) | THRBTDP1APEX1PDK2KMT2A | |
| SCHEMBL6316881 | 0.75 | PDK2 (0.50) | THRBTDP1APEX1PDK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| EP-2026761-B1 | INHALANT PROPELLANT-FREE AEROSOL FORMULATION | BOEHRINGER INGELHEIM INT (DE) | 2020-04-15 | — | — | EP | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-1651224-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | Boehringer Ingelheim International GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060058335-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-03-16 | — | — | US | disclosed |
| US-6998406-B2 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-14 | — | — | US | disclosed |
| WO-2005013994-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6815452-B2 | ANTIASTHMATIC AND ANTISPASMODIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Boehringer Ingelheim Pharma KG & Co GmbH (DE) | 2004-11-09 | — | — | US | disclosed |
| US-6790856-B2 | TROPANE 9-FLUORENE-9-CARBOXYLATE DERIVATIVES FOR TREATMENT ASTHMA, CHRONIC OBSTRACTIVE PULMONARY DISEASE, VAGALLY INDUCED SINUS BRADYCARDIA, HEART RHYTHM DISORDERS, SPASM IN URINARY OR GASTROINTESTINAL TRACTS AND MENSTRUAL PAIN | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-09-14 | — | — | US | disclosed |
| US-20040157832-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-12 | — | — | US | disclosed |
| US-20030199539-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | THRB 1837/4885TDP1 2364/4885APEX1 2133/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | THRB 1226/4885TDP1 4836/4885APEX1 1947/4885 |
| US-20050020622-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, F12 | THRB 3332/4885TDP1 2753/4885APEX1 3742/4885 |
| US-20030199539-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | AFF1, FPR1, AFF4 | THRB 3645/4885TDP1 3359/4885APEX1 4192/4885 |
| US-20040157832-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, FPR3 | THRB 3281/4885TDP1 2599/4885APEX1 3655/4885 |
| US-20060058335-A1 | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments | FPR1, AFF1, F12 | THRB 3332/4885TDP1 2753/4885APEX1 3742/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | THRB 1526/4885TDP1 4831/4885APEX1 3837/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | THRB 804/4885TDP1 3302/4885APEX1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.